Diagnosis of non‐alcoholic fatty liver disease/non‐alcoholic steatohepatitis: Why liver biopsy is essential


The pattern of non‐alcoholic fatty liver disease is complex with an association of several lesions, each of them related to different pathophysiological mechanisms. Despite the progress in non‐invasive tools, liver biopsy remains the only diagnostic procedure that can reliably assess these various patterns, their related severity and associations. The most important difficulties of liver biopsy can be avoided if this procedure is performed by an experienced hepatologist and read by a liver pathologist. However, for obvious reasons, biopsy should be restricted to selected patients, especially in the context of clinical trials. Indeed, liver biopsy is considered mandatory by regulatory authorities as a surrogate to assess drug efficacy in Phase 3 clinical trials. In addition to the clinical diagnosis, liver biopsy can be used to score the various histological patterns of disease (NASH‐CRN, SAF scores) and accurately assess the extent of fibrosis, both of which are useful when follow‐up biopsies are performed. When treatment becomes available in the near future, liver biopsy could remain useful for choosing the most suitable therapeutic option based on the main predominant histological features (activity, steatosis, fibrosis).


liver biopsy, non‐alcoholic fatty liver disease, personalized treatment


About Speaker


MD, Phd, Director of the Department of Pathology


City: Paris

Institution: Hôpital Beaujon

Contact: pierre.bedossa@bjn.aphp.fr

Biography of Pierre BEDOSSA

Pierre Bedossa is a professor of pathology. He served as chairman of the Department of Pathology, Physiology, Nuclear Medicine and Imaging from The University Hospitals of Paris Nord-Val de Seine, France. He is now Medical Director and CEO of Liverpat, a company dedicated to pathology in clinical research. His main topics of interest are dynamic of fibrosis and NASH. He led several international groups of pathologists including the METAVIR, the FLIP and the LITMUS pathology consortium. He has published more than 400 original articles in peer-reviewed journals.

View more